Active, not recruitingPhase 3NCT05913037
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Studying Neurofibromatosis type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- Principal Investigator
- Wenbin Li, MDBeijing Tiantan Hospital
- Intervention
- Test group (Group A): FCN-159 8 mg, orally, once daily;(drug)
- Enrollment
- 167 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2023 – 2025
Study locations (15)
- Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing Municipality, China
- Plastic Surgery Hospital,Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
- The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- Renmin Hospital of Wuhan University, Wuhan, Hubei, China
- TongJi Hospital，TongJi Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
- The First Hospial of China Medical University, Shenyang, Liaoning, China
- Fudan University Shanghai Cancer center, Shanghai, Shanghai Municipality, China
- West China Hospital，Sichuan University, Chengdu, Sichuan, China
- Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
- Zhejiang Provincial People'S Hospital, Hanzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05913037 on ClinicalTrials.govOther trials for Neurofibromatosis type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06507748A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University
- RECRUITINGNANCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)AstraZeneca
- RECRUITINGNANCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca
- RECRUITINGPHASE1NCT06961565PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPasithea Therapeutics Corp.
- RECRUITINGNANCT06880991Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative StudyNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06541847A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1Healx Limited
- RECRUITINGNANCT06222203Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI)